Athanasios Kotsakis

Athanasios Kotsakis, MD, PhD, is a professor of Medical Oncology at the Medical School of the University of Thessaly and the director of the University Oncology Clinic at the University Hospital of Larissa.

He studied at the Medical School of the University of Athens and completed his PhD with honors at the Medical School of the University of Crete, focusing on a prospective study of the action of anti-neoplastic drugs on T-lymphocytes. From 2008-11 he was appointed as a Research Fellow in the University of Pittsburgh Medical Center (UPMC), Dept. of Medical Oncology, Pittsburgh, Pennsylvania, USA & in Dept. of Immune Monitoring and Cellular Processing Laboratory (IMCPL), Pittsburgh, Pennsylvania, USA. He was nominated Lecturer of Medical Oncology at the Medical School of University of Crete in 2009 and Assistant Professor of Medical Oncology in 2014 at the same University and in 2017 elected Associate Professor of Medical Oncology, Department of medicine, School of Health Sciences, University of Thessaly and in 2022 elected Professor at the same University. He is also the President of Hellenic Society of Immuno-Oncology since 2015, coordinator in the lung cancer group of the Hellenic Oncology Research Group (HORG) since 2014 and Faculty Μember of Tumour Immunology and Immunotherapy of the European Society for Medical Oncology (ESMO).

Prof. Kotsakis is a member of various International Scientific Societies including the American Society of Clinical Oncology (ASCO), the International Association for the study of Lung Cancer (IALSC) & EORTC (European Organization for Research and Treatment of Cancer). His primary areas of research and ongoing activity are lung cancer, pancreatic cancer and head and neck cancer, with a focus on investigating molecular changes that characterize these tumors. He also has a significant interest in immuno-oncology and understanding mechanisms related to immune therapy responses and resistance.

His curriculum vitae highlights include the authorship of 6 chapters in international medical books, 167 publications in international journals (SCI), 9 publications in non-SCI journals, 200 presentations at international conferences, 80 presentations at Greek conferences, and approximately 120 speeches at international and Greek conferences. The total citations of his published work amount to 5657 (with 37 self-citations), his h-index (Google Scholar) is 42. Additionally, he holds a patent for the study titled "Use of cabazitaxel in patients with metastatic NSCLC progressing after docetaxel-based treatment," with patent number EP 13306252.1, filed on September 12, 2013, and US 62/013,231, filed on June 17, 2014.